Device Trial Radar · NCT07924215
PureSee EDOF Versus ZCB00 Monofocal IOLs in Mild-to-Moderate Glaucoma
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Dec 2, 2026
Primary completion
Oct 29, 2027
Study completion Oct 29, 2027
Sponsor
- Lead sponsor
- Mann Eye InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sengi
- First posted
- Nov 9, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single center, ambispective study of visual outcomes after successful bilateral cataract surgery in patients with mild to moderate primary open-angle glaucoma (POAG). Two cohorts are compared: patients with bilateral implantation of the TECNIS PureSee non-diffractive extended depth of focus intraocular lens (EDOF IOL) and patients with bilateral implantation of the TECNIS ZCB00 monofocal IOL.
Conditions
- Primary Open-Angle Glaucoma
Interventions
TECNIS PureSee Intraocular LensDevice
Bilateral implantation of the TECNIS PureSee non-diffractive extended depth of focus intraocular lens (toric and non-toric) at cataract surgery.
TECNIS ZCB00 Monofocal Intraocular LensDevice
Bilateral implantation of the TECNIS Monofocal Intraocular Lens ZCB00 (toric and non-toric) at cataract surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Distance visual acuity - binocular distance-corrected visual acuity (DCVA)Time frame: 3 to 18 months following second-eye cataract surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mann Eye Institute
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.